Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects

AIM: Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. The combination of a DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of the present study was to evaluate the pharmac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug Des Devel Ther
Hauptverfasser: Hwang, Inyoung, Kim, Yun, Yoo, Hyounggyoon, Jang, In-Jin, Yu, Kyung-Sang, Lee, SeungHwan
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove 2020
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7591087/
https://ncbi.nlm.nih.gov/pubmed/33122892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S275336
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge